Sign Up Today and Learn More About Laronde Stock
Invest in or calculate the value of your shares in Laronde or other pre-IPO companies through EquityZen's platform.
Laronde Stock (LARO)
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
About Laronde Stock
Founded
2017
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.
Laronde Press Mentions
Stay in the know about the latest news on Laronde
Alltrna raises $109M for 'transfer RNA' drug vision
biopharmadive • Dec 20, 2023
Laronde, Senda Biosciences merge to create new Flagship ...
biopharmadive • Dec 20, 2023
Flagship's embattled Laronde sets sail with Senda in merger
fiercebiotech • Oct 20, 2023
Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boom
statnews • Jun 19, 2023
The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner
bizjournals • May 11, 2023
Laronde Management
Leadership team at Laronde
Co-founder and Chairman of the Board
Noubar Afeyan
Co-founder & Board of Directors
Avak Kahvejian
Join now and verify your accreditation status to gain access to:
- Laronde current valuation
- Laronde stock price
- Available deals in Laronde and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Laronde stock?
Accredited investors can buy pre-IPO stock in companies like Laronde through EquityZen funds. These investments are made available by existing Laronde shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Laronde stock?
Shareholders can sell their Laronde stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
